Posted by Mike Sweeney on Mon, Oct 04, 2010 @ 06:25
Greg Zeng of Zacks has reconfirmed his $8.00 price target for Access Pharma (OTCBB: ACCP) and he stated his belief that "third quarter financials are expected to be better than our estimates."
Highlights in Zeng's update included:
- On September 14, 2010, Access received its first commercial order for MuGard from BioScrip, its specialty distribution partner. BioScrip's initial purchase order of MuGard was over $700,000. This amount will provide adequate inventory for its various distribution channels to support Access’ first phase of its product launch for MuGard.
- Access Pharmaceuticals has inventory on hand and will begin shipping product to BioScrip immediately. BioScrip’s order represents Access’ first sales of MuGard in the US after the company officially launched MuGard in August 2010.
- Access signed two distribution and marketing agreements in the US, one with BioScrip and one with iMedicor/DMS earlier this year.
- On September 21, 2010, Access signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
- Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals Limited in Shenzhen, China in an effort to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan.
Zack's initial estimate for the third quarter sales of MuGard was $0.5 million, which they now feel is low.
ACCESS PHARMACEUTICALS (ACCP): Zacks Research Report
Access Pharma also announced last week that they had made "Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA." As a result of the continued advancements made with its Cobalamin program, Access rebranded the targeted-drug delivery technology as CobaCyte™; and submitted additional patent applications for its improved CobaCyte formulations, including siRNA compositions.
Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
Proof-of-Principle Data for Proprietary CobaCyte Platform in siRNA
Posted by Mike Sweeney on Tue, Sep 21, 2010 @ 02:42 PM
ACCP Stock Video Chart @ ProActive Newsroom
Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).
Posted by Mike Sweeney on Tue, Sep 21, 2010 @ 10:51
Access Pharmaceuticals, Inc. (OTCBB: ACCP) announced that they signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, a a global pharmaceutical business development firm, with special focus on bringing core medicines from the U.S., Europe and Japan into the fast-growing South-East Asian marketplace. 
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.
This announcement continues to position ACCP as one of the few (only?) Small-Cap stocks with revenues and a product that IS on the market. Jeffrey Davis, CEO of Access stated in the press release, "The recent news surrounding MuGard, including this agreement and the initial product purchase order received in the US, underscores the significant revenue potential we believe MuGard will provide our company."
The press release also stated:
"Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories. Coinciding with the signing of the above agreement, Access also approved a sub-license agreement between RHEI Pharmaceuticals and Jian An Pharmaceuticals ("Jian An") Limited in Shenzhen, China in an effort to leverage Jian An's extensive sales, marketing and regulatory infrastructure for the launch of MuGard in China and Taiwan.
Jian An is headquartered in Shenzhen, China and has a 25-year history of selling pharmaceutical and other medical products in the China market. Jian An has 1400 sales representatives covering all majors centers in China through 169 sales offices. With Jian An's sales and marketing infrastructure and the supply agreement which will provide up to $30 million of MuGard to the territory, Access Pharmaceuticals' commercialization efforts remain on track in China and its other South East Asian territories. Access retains its existing milestone and royalty structure for the territory. In addition, Access and RHEI have also filed a new patent application in China covering MuGard for the relief and reduction of erythema. This new application is expected to provide additional IP protection as well as the potential for a new indication for MuGard."
They are experts in business development, regulatory approval and clinical development and have a management team that combines a Western approach to pharmaceuticals with a long experience in Europe, North America and South-East Asia. They use their development capabilities and network of preferred commercial partners to help other pharmaceutical companies introduce their products into specific niche markets, such as the European institutional health care market and the Chinese hospital market. RHEI is headquartered in Hong Kong and has operations in Belgium, the US and China. www.rheipharma.com
Posted by Mike Sweeney on Wed, Sep 15, 2010 @ 12:41 PM
Following yesterday's Blog on the first order for MuGard, Access Pharmaceuticals (OTCBB: ACCP) launched a product specific website at www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
In a press release, Frank Jacobucci, VP of Sales and Marketing for Access Pharma stated:
"We are proud to have launched our product website as it resource for patients and healthcare professionals," said Frank Jacobucci, VP of Sales and Marketing for Access Pharmaceuticals, Inc. He continued, "Keeping the patient in mind, we constructed an easy-to-navigate MuGard destination where both patients and doctors can go to learn about oral mucositis, symptoms and the benefit that MuGard provides someone undergoing radiation and chemotherapy for various types of cancers, including head and neck cancers, such as throat cancer. By starting MuGard on the first day of anticancer regimens, as shown in the clinical data, a significant number of patients can significantly reduce the occurrence, duration and severity of oral mucositis. MuGard – first day, every day."
Full Press Release
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Characterized Up to 40% of all patients receiving chemotherapy develop moderate to severe mucositis, and almost all patients receiving radiation for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, visit www.MuGard.com.
Posted by Mike Sweeney on Tue, Sep 14, 2010 @ 01:11 PM
Hard work pays off. It is somewhat rare to see a small BioPharm company sell a product as many are sold off to Big Pharma before they reach a commercial market launch. Today, Access Pharma (OTCBB: ACCP) received an order for $700,000 of their MuGard product from BioScrip (Nasdaq:BIOS), its specialty distribution partner. In an ACCP Press Release today, the Company stated that BioScrip's initial purchase order of MuGard will provide inventory for their various distribution channels to support the Company's first phase of its product launch for MuGard. Access Pharmaceuticals has inventory on hand and will begin shipping product to BioScrip immediately. MuGard is an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiation and/or chemotherapy
Jeffrey Davis, CEO of Access Pharmaceuticals stated in a press release:
"After months preparing for the official North American MuGard launch, this commercial order represents a significant milestone as it marks Access' first sales of MuGard in the US,With the help of our partners, especially BioScrip, we continue to broaden our reach within the medical community to further strengthen MuGard's position as the optimal treatment option for oral mucositis currently on the market."
ACCP has signed two distribution and marketing agreements in the US, with BioScrip and iMedicor/DMS. BioScrip is a leader in comprehensive pharmacy services, provides nationwide distribution for MuGard with its extensive physician relationships, 30+ top metro BioScrip specialty pharmacies, mail distribution capability and diversified payor network.
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access' products include ProLindac™, currently in Phase II clinical testing of patients with ovarian cancer, and MuGard™ for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
Posted by Mike Sweeney on Thu, Sep 02, 2010 @ 04:28 PM
Now with the Michael Douglas' cancer story out there, ACCP's MuGard story was picked up at OTC Showcase.
"The news of Michael Douglas and his throat cancer announcement last night on “Late Night with David Letterman” is trending everywhere on the web. It was top subject on Twitter and is covering front pages of websites. On Letterman, Michael
announced that his cancer was detected three weeks ago and that it has been diagnosed as in being in “stage 4.” Mr. Douglas also stated that he just began his first round of radiation and chemotherapy as therapy.
While well-wishes, thoughts and prayers are being sent to Michael from every source that discusses the topic (and my family sends ours as well), I can’t help myself from thinking about mucositis. Perhaps I spend too many hours digging through emerging biotechnology companies and the compounds that some of them possess. Be that as it may, it is still a genuine concern of those afflicted with cancer.
Mucositis is a frequent adverse effect from chemotherapy and radiation treatments. Technically, it is defined as “the painful inflammation and ulceration of the mucous membranes lining the digestive tract.” While mucositis can appear anywhere in the gastrointestinal tract, oral mucositis specifically refers to ulcerations and/or inflammations within the mouth. There are several levels to oral mucositis, all of which can be very painful, but Grade 3 (unable to eat solid foods) and Grade 4 (unable to eat solid food or drink liquids) are particularly debilitating."
Full Story @ OTC Showcase
Posted by Mike Sweeney on Wed, Sep 01, 2010 @ 01:42 PM
Jeffrey Davis is the CEO of
Access Pharmaceuticals (OTCBB: ACCP) which is an emerging oncology-focused specialty pharmaceuticals company (January 2008 to present). The OutsideIn Research interview is broken into two sections:
- Part I - covers Access Pharma's strategy and its first product MuGard, which is in product launch now, and
- Part II - covers Access Pharma's three products in the pipeline, Cobalamin, ProLindac, and Thiarabine.
Here is Part II at OutsideIn Research.
Posted by Mike Sweeney on Sat, Aug 21, 2010 @ 07:56
ACCP Tech Trade - August 21, 2010
Posted by Mike Sweeney on Fri, Aug 20, 2010 @ 09:05
Jeffrey Davis is the CEO of
Access Pharmaceuticals (OTCBB: ACCP) which is an emerging oncology-focused specialty pharmaceuticals company (January 2008 to present). The OutsideIn Research interview is broken into two sections:
- Part I - covers Access Pharma's strategy and its first product MuGard, which is in product launch now, and
- Part II - covers Access Pharma's three products in the pipeline, Cobalamin, ProLindac, and Thiarabine.
Here is Part I at OutsideIn Research.
Posted by Mike Sweeney on Thu, Aug 19, 2010 @ 12:50 PM
Grand Zeng of Zacks Research issued an update yesterday on their "Outperform" rating on Access Pharmaceuticals (OTCBB: ACCP) with a six month price target of $8.00. ACCP is trading today at $1.95.
Download Zacks' ACCP Update - 8/18/10
Zacks Equity Research combines quantitative models with the insight provided by experienced equity analysts to create superior long-term stock recommendations.
Access Pharmaceuticals, Inc. (OTCBB: ACCP) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).